Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06403709
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-04-01
Brief Title:
Irinotecan TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization Data
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Class:
OTHER
Study ID:
SH-2023005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None